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Abstract: Salmonella enterica serovar Typhimurium preferentially colonizes tumors in vivo 
and has proven to be an effective biologic vector. The attenuated S. enterica Typhimurium 
strain χ4550 was engineered to express truncated human interleukin-2 and renamed SalpIL2. 
Previously, we observed that a single oral administration of SalpIL2 reduced tumor number and 
volume, while significantly increasing local and systemic natural killer (NK) cell populations 
in an experimental metastasis model. Here we report that in nontumor-bearing mice, a single 
oral dose of SalpIL2 resulted in increased splenic cytotoxic T and NK cell populations that 
returned to control levels by 4 weeks post oral administration. Though SalpIL2 was detected 
in mouse tissues for up to 10 weeks, no prolonged alterations in peripheral blood serum chem-
istry or complete blood cell counts were observed. Similarly, comparative histopathological 
analysis of tissues revealed no significant increase in pyogranulomas in SalpIL2-treated animals 
with respect to saline controls. In Rag-1 knockout mice, which have severely impaired B and 
T cell function, SalpIL2 reduced growth of hepatic metastases. Furthermore, SalpIL2 altered 
expression of several proinflammatory cytokines and chemokines in the serum of mice with 
pulmonary osteosarcoma metastases. These data further suggest that SalpIL2 is avirulent and 
induces a cell-mediated antitumor response.
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Introduction
Patients diagnosed with distant metastases of colorectal adenocarcinoma and 
  osteosarcoma have 11% and 30% 3-year survival rates, respectively.1,2 In contrast, 
patients with localized osteosarcoma or colon cancer achieve nearly 70% 3-year 
and 90% 5-year survival, respectively.1,3 Therefore, development of early detection 
  techniques and more efficient tumor-targeting therapies are needed to improve survival 
in patients with metastatic tumors.
Salmonella enterica serovar Typhimurium is a Gram-negative intracellular facul-
tative anaerobe transmitted via the fecal-oral route. After oral ingestion, Salmonella 
invades the intestinal epithelia, colonizes Peyer’s patches, and enters the lymphatics 
and bloodstream by infecting inactivated macrophage and dendritic cells. The bacteria 
then escapes to systemic tissues including the liver, spleen, and lungs. In addition, 
  attenuated S. enterica preferentially invade and multiply within tumors relative to normal 
tissue.4–6 We engineered an attenuated strain of S. enterica Typhimurium, χ4550, to 
express a truncated human interleukin-2 (IL-2) protein and named it SalpIL2. A single 
oral dose of SalpIL2, in animals with established pulmonary osteosarcoma metastases, 
significantly reduced tumor burden while increasing pulmonary natural killer (NK) cell Biologics: Targets & Therapy 2010:4 62
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populations as compared to non-IL2-expressing S. enterica 
and saline controls.7 Furthermore, SalpIL2 oral administra-
tion prior to tumor injection prevented the establishment 
of metastatic tumors and increased splenic and hepatic NK 
cell populations.8,9 Although SalpIL2 tracks to established 
tumors, it is unknown whether its antitumor effect is com-
pletely immune cell-mediated or is directly toxic to tumor 
cells in vivo.
Here we seek to further characterize the antitumor effect 
of a single oral administration of SalpIL2 in experimental 
mouse tumor models. In a murine infection model, SalpIL2 
was avirulent and immunogenic, and within 16 weeks after 
oral administration colony-forming units (CFU) were no 
longer detectable in nontumor tissues, including the spleen, 
liver and lungs. Oral administration of SalpIL2 resulted in 
a maximal increase of splenic NK cell populations within 
14 days and decreased metastatic hepatic tumor burden in 
a T cell-independent manner. Lastly, oral administration of 
SalpIL2 in tumor-burdened animals significantly altered the 
abundance of several proinflammatory serum cytokines. 
These data strongly suggest that SalpIL2 is highly immuno-
genic, reduces tumor burden and tumor-associated systemic 
inflammation, while increasing proliferation of tumor-target-
ing cytotoxic NK cells.
Materials and methods
Tumor cells
Mouse osteosarcoma K7M2 (ATCC no. CRL-2836) and 
colon adenocarcinoma MCA-38 cells were maintained and 
prepared as previously described.7,9 All cultured cells were 
used within 18 passages from the master cell bank and 
were greater than 90% viable as determined by trypan blue 
exclusion.
Bacteria
The attenuated S. enterica Typhimurium strain  χ4550 was 
a kind gift from Dr. Roy Curtiss III (Washington University, 
St. Louis, MO). Plasmid constructs with or without a 
  truncated C-terminal human interleukin-2 gene were elec-
troporated into χ4550 and the resulting strains were named 
SalpIL2 and Sal-NG, respectively.
Animals
Bacterial administration
All animals were orally administered 200 µL of Hank’s 
buffered salt solution (HBSS) or HBSS containing 2 × 108 
CFU Sal-NG or SalpIL2 and monitored for 15 minutes to 
ensure the bacteria were not aspirated. All mice were housed 
under the strict care of the University of Minnesota Research 
Animal Resources in a biosafety level 2 facility.
Biodistribution
Six to eight-week-old female C57BL/6 mice were gavage 
fed either saline or SalpIL2 or Sal-NG. Mice were harvested 
weekly for 4 weeks to determine tissue toxicity of SalpIL2 
or Sal-NG. In an additional experiment, 110 16 to 20-week-
old female C57BL/6 mice were randomly separated and 
orally administered either saline or SalpIL2 and sacrificed as 
described below.
harvest procedure
On days 3, 7, 14 and biweekly until week 16, randomly 
selected groups of (n = 5) saline and SalpIL2-treated mice 
were anesthetized with a ketamine/xylazine (1:2) combina-
tion. Animal tissues were aseptically harvested and separated 
for determination of S. enterica CFU per gram of tissue 
or placed in 10% formalin and submitted for independent 
pathology analysis. The tissues analyzed included the heart, 
thymus, brain, lung, liver, spleen, stomach, small intestine, 
large intestine, bone marrow, intra-abdominal lymph nodes 
and kidneys. Formalin-fixed tissues were examined for 
pathological signs of Salmonella infection or IL-2 toxic-
ity by Charles River Laboratories, Pathology Associates, 
Maryland (PAI). For determination of S. enterica CFU, half 
of each aforementioned tissue was weighed and mechanically 
minced to a homogenous slurry in 4°C phosphate-buffered 
saline (PBS) with sterile glass stoppers. Bone marrow was 
collected by aseptic removal and perfusion of the femur with 
sterile PBS. In addition, urine and feces were aseptically col-
lected from the bladder and large intestine. All tissues and 
bodily fluids were cultured in triplicate on MacConkey II 
and Hektoen agar plates overnight.
Serum collection
Peripheral blood at all experimental endpoints collected from 
the right atrium of anesthetized animals was analyzed for 
complete blood count (CBC), centrifuged for serum chem-
istries or stored at –20°C for cytokine analysis.
Serum chemistries
Glucose, aspartate aminotransferase (AST), alanine trans-
aminase (ALT), alkaline phosphatase (Alk Φ), bilirubin, 
cholesterol, total protein (TP), albumin, globulin, blood 
urea nitrogen (BUN), creatinine, phosphorous, calcium, 
sodium, potassium, chloride, bicarbonate, anion gap and   
gamma-glutamyl  transferase  (gamma-GT)  serum 
concentrations were examined by the University of Biologics: Targets & Therapy 2010:4 63
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Minnesota’s Research Animal Resources’ in-house veterinary 
laboratory.
complete blood cell counts
White blood cells (WBC), neutrophils (NE), lymphocytes 
(LY), monocytes (MO), eosinophils (EO), basophils (BA), 
red blood cells (RBC), mean corpuscular volume (MCV), 
hemoglobin (Hb), hematocrit (HCT), mean corpuscular 
hemoglobin (MCH), mean corpuscular hemoglobin concen-
tration (MCHC), red blood cell distribution width (RDW), 
platelets (PLT), mean platelet volume (MPV), packed cell 
volume (PCV), and total plasma protein (TPP) were ana-
lyzed by the University of Minnesota’s Research Animal 
Resources’ in-house veterinary laboratory.
Pcr analysis of Salmonella colonies
Colonies morphologically similar to S. enterica Typhimurium 
were confirmed to be SalpIL2 by polymerase chain reaction 
(PCR) for the presence of the plasmid containing truncated 
interleukin-2 sequence. The forward primer 5-TGAATTG 
GAAGATCTTCCGG-3 anneals 127 nt upstream from the 
transcription start site of the truncated IL-2 and the reverse 
primer 5-GTTTTGGCGGATGAGAGAAG-3 anneals 
4 nt downstream from the truncating stop codon resulting 
in a PCR product of 587 bp. PCR products were run on 
2% agarose gels against no template controls and known 
  SalpIL2 stock as controls to ensure maintenance of plasmid 
in vivo and identification of the genotype.
Splenic lymphocyte response to Salmonella
In duplicate experiments, 100 6 to 8-week-old C57BL/6 
female mice were orally administered saline, Sal-NG, or 
SalpIL2 as described above. Cohorts of animals (n = 5) were 
sacrificed 3, 7, 14, 21 and 28 days after oral gavage for collec-
tion of splenic mononuclear cells. Lymphocytes were stained 
with rat antimouse conjugated antibody (BD Pharminogen, 
San Diego, CA) using previously described methods and iden-
tified with a FACScalibur flow cytometer (Becton Dickenson, 
Grenoble, France) and analyzed with Cell Quest Pro Software 
(Becton Dickenson, San Jose, CA).9 Lymphocyte popula-
tions were identified using forward scatter versus side scatter 
profiles and gated for mononuclear lymphocytes. NK, CD8+ 
and CD4+ cell populations were identified by single-positive 
populations based on 10,000-gated events.
Tumor metastasis models
Six to eight-week-old female Balb/c and Rag-1-/- mice were 
acquired from Harlan Sprague Dawley (Indianapolis, IN). 
Mice were orally gavaged 7 days prior (prophylactic model) 
or 3 days after tumor injection (treatment model) with 
standardized bacterial stocks as previously described.7 In 
triplicate experiments, 2 × 105 K7M2 osteosarcoma cells were 
injected in the left lateral tail vein. Additional mice were sac-
rificed for hematoxylin and eosin (H&E) analysis of animals 
in prophylactic and treatment osteosarcoma models. Asepti-
cally removed lungs were submitted for H&E analysis by the 
University of Minnesota’s Histopathology core. In the hepatic 
metastasis model, mice were injected with 5 × 104 MCA-38 
colorectal cancer cells as previously described.9 Mice were   
separated into the following groups: 2 saline controls (no 
tumor injection), 5 C57BL/6 controls, 9 Rag-1-/- saline 
  controls, 8 Rag-1-/- Sal-NG, and 10 Rag-1-/- SalpIL2.
cytokine analysis
Serum was collected from mice with K7M2 pulmonary 
metastasis at the time of sacrifice. Samples were loaded into 
a 96-well plate and analyzed following manufacturer’s guide-
lines with a Bio-Plex 23-Murine Cytokine Assay (Bio-Rad, 
Hercules, CA) on the Bio-Plex 200 Array Reader.
Statistical analysis
Statistical tests were performed with StatView software 
(v. 5.0.1; SAS Institute, Cary, NC). CFU/cell and serum 
cytokines in osteosarcoma experiments and hepatic lympho-
cyte populations and tumor volume in Rag-1-/- mice were 
entered for each specimen at the experimental endpoint to 
calculate the total mean values for each treatment group. 
Statistical significance between groups were determined by 
Fisher’s exact test. Values from splenic lymphocytes, CBC 
and serum chemistries were entered for each mouse at the 
experimental endpoint to calculate the total mean values for 
each treatment group. Statistical significance between groups 
was determined by Students’ unpaired t-test for serum and 
CBC and Fisher’s exact test for splenic lymphocytes.
Results
Biodistribution of SalpIL2
C57BL/6, in contrast to Balb/c mice, have an exaggerated 
Th-1 cell-mediated immune response and is the genetic 
background for many transgenic knockout animals including 
the Rag-1-/- T-cell knockout strain.10,11 Thus, C57BL/6 is a 
model strain for examining the virulence of an attenuated 
intracellular pathogen. Salmonella infection appears to be 
age dependent in C57BL/6 mice, as animals under 24 weeks 
are significantly more resistant to infection than their aged 
counterparts.12 In this study, 6 to 8-week-old C57BL/6 
mice orally administered Sal-NG and SalpIL2 showed no Biologics: Targets & Therapy 2010:4 64
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significant differences in the presence of pyogranulomas, 
CBC or serum chemistries up to 4 weeks following inocula-
tion (data not shown). We next examined the biodistribution 
and toxicity of SalpIL2 in 16 to 20-week-old C57BL/6 mice 
compared to saline controls over 16 weeks (Table 1). SalpIL2 
CFU were recovered from the liver and spleen as early as 
2 hours post oral administration and detected in the spleen 
of all treated animals at the 1-week sacrifice. Detectable 
SalpIL2 colonies remained high until week 4, after which 
there was a progressive decrease in the number of positive 
mice. Except for CFU in the stomach of one animal at weeks 
6 and 10, SalpIL2 was cleared from the digestive tract within 
1 week. We did not detect SalpIL2 in the bone marrow, urine 
or blood at any time point during the experiment and it was 
only observed in the fecal material in a single animal during 
the first 14 days (data not shown). Animals tested positive 
for SalpIL2 in the lung for up to 6 weeks, and an increasing 
number of SalpIL2 CFUs were observed in the lung over 
time. Acute CFU concentrations decreased in gastrointestinal 
tract tissue within one week of oral infection, but remained 
elevated in organs with major capillary beds (lung, liver, and 
spleen) or with significant immune involvement (thymus 
and intra-abdominal lymph nodes). Detection of CFUs in 
the heart and brain were limited to only one mouse per time 
point. Except for the intra-abdominal lymph nodes, SalpIL2 
CFU concentrations decreased in all tissues by week 6 and 
CFU were not detected in any animal after week 10.
Serum and cBc
Oral administration of SalpIL2 increased serum chloride 
concentration compared to saline controls within 2 hours 
(115.33 mmol/L vs 110.75 mmol/L respectively; P  0.05) 
(Figure 1). By day 3, mean platelet volume (MPV) decreased 
in SalpIL2-treated animals relative to controls (4.78 fL 
vs 5.50 fL; P  0.01), and the number of platelets (PLT) 
increased (1053 vs 615; P  0.05) (Figure 3). Also by day 
3, in animals treated with SalpIL2 vs controls: EO increased 
(0.054 K/µL vs 0.002 K/µL; P  0.05), MO increased 
(0.204 K/µL vs 0.090 K/µL; P  0.05), NE increased 
(0.604 K/µL vs 0.210 K/µL; P  0.0209), and WBCs 
increased (3.854 K/µL vs 2.132 K/µL; P  0.0284) (Figure 2). 
By week 4, RDW significantly decreased with SalpIL2 treat-
ment (0.189% to 0.202%; P  0.05). Although RDW values 
in SalpIL2-treated animals did not vary between weeks 4 
and 6, control values decreased 20% and by week 6 SalpIL2-
treated animals had significantly increased RDW relative to 
controls (0.194% vs 0.180%; P  0.01) (Figure 3), Also in 
week 6, in animals treated with SalpIL2, MCV decreased 
(40.2 fL vs 42.7 fL; P  0.01) (Figure 3), and the amount 
of Alk  increased (96.25 U/L vs 84.33 U/L; P  0.05) 
(Figure 1). In week 8, SalpIL2 treated animals had decreased 
MCV (39.06 fL vs 41.92 fL; P  0.05) (Figure 3) and 
increased phosphorous (8.3 mg/dL vs 5.5 mg/dL; P  0.05) 
  (Figure 1). At week 14, decreases were observed in creati-
nine (0.100 mg/dL vs 0.175 mg/dL; P  0.05) and BUN 
(20 vs 28; P  0.01) (Figure 1). Differences in remaining 
serum and blood chemistries examined were determined to 
be statistically insignificant.
histopathology
Microscopic histopathological analysis revealed that 
the liver in SalpIL2-treated animals underwent the most 
changes of all tissues examined. Pyogranulomas defined as 
aggregations of neutrophils, macrophages and mononuclear 
Table 1 cFU per gram tissue of a single oral gavage of 108 cFU of SalpIL2 in naïve 16- to 20-week-old c57BL/6 mice. results are mean 
values from animals with SalpIL2 positive CFU. Numbers in parentheses represent the number of animals out of five with detectable 
SalpIL2 in the respective tissue. SalpIL2 was not detected in tissue from control animals at any harvest time
Time 2 h 3 d 1 w 2 w 4 w 6 w 8 w 10 w 12 w 14 w 16 w
Thymus 2.67 (1) – – – 3.41 (1) – – – – – –
Brain – – 3.04 (1) 3.09 (1) 2.65 (1) – – – – – –
Stomach 2.99 (3) – – – – 2.24 (1) – 2.95 (1) – – –
S intestine 3.82 (2) 3.76 (1) – – – – – – – – –
L intestine 4.30 (2) – – – – – – – – – –
Lymph 2.28 (2) – 3.34 (1) 2.99 (2) 3.12 (3) 3.93 (1) – 3.97 (1) – – –
Lung 1.74 (1) 4.51 (2) 3.34 (3) 3.56 (1) 2.93 (3) 2.22 (1) – – – – –
heart – 2.24 (1) – 3.45 (1) – – – – – – –
Kidney 2.29 (1) – – – – 1.97 (1) – 2.49 (1) – – –
Liver 1.68 (2) 2.68 (3) 2.21 (4) 2.67 (2) 2.41 (4) 2.29 (1) – 2.01 (1) – – –
Spleen 2.38 (1) 3.26 (3) 3.39 (5) 4.06 (4) 4.14 (5) 3.40 (3) 2.87 (3) 3.11 (1) – – –
Abbreviations: cFU, colony-forming units; h, hours; d, days; w, weeks.Biologics: Targets & Therapy 2010:4 65
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lymphocytes were present in the liver at 3 and 7 days post 
oral gavage in two of five mice and classified as mild to 
moderate. At week 2, three of five livers had mild to mod-
erate pyogranulomas and by week 4 all livers had multifo-
cal pyogranulomas that were classified as mild (1 of 5) or 
moderate (4 of 5). At 6 and 8 weeks, four of five livers in 
each treatment group had multifocal pyogranulomas graded 
as minimal or mild. At 10 weeks, three of five livers in the 
SalpIL2 group had mild to moderate pyogranulomas. Sal-
pIL2-treated mice at weeks 12 and 14 had minimal (focal) 
pyogranulomas with one liver at each time point having 
multifocal lesions. By week 16, all pyogranulomas in Sal-
pIL2-treated livers were graded as mild or were no longer 
present in treated mice. In contrast, the saline-treated animals 
had minimal to mild pyogranulomas in the liver at 6, 10, 12 
and 16-week sacrifices. Acute Kupffer cell hyperplasia was 
detected in as many as four of five SalpIL2-treated mice at 
1, 2, and 4 weeks post oral gavage and one of five livers 
had the increase at weeks 6, 8, and 10. No control animals 
had Kupffer cell hyperplasia.
Spleens from SalpIL2-treated animals displayed increased 
myelopoiesis from day 3 to week 4 after oral administration, 
followed by a steady decrease from weeks 6 through 14. 
Erythropoiesis was observed in tissues from SalpIL2-treated 
animals collected at 2 hours and on day 14. Although a rare 
occurrence, spleens of control animals showed increased 
erythropoiesis on day 3 and contained multiple mild pyo-
granlomas at week 4. Similarly, one control lung sample had 
moderate pyogranulomas present on day 3 and one animal in 
the 4- and 8-week sacrifices had minimal pulmonary pyogran-
ulomas accompanied by increased pulmonary neutrophils.
Bone marrow tissue displayed mildly increased myelo-
poiesis as soon as 3 days after administration, moderate 
myelopoiesis by 2 weeks and mild to obvious myelopoiesis at 
4 weeks. Minimal myelopoiesis was present at 6 and 8 weeks 
in treated animals and continued to decrease until week 14.   
160
120
80
40
0
Chloride
Phosphorous
*
*
**
*
*
Creatinine
A B Alk φ Urea N
Week
U
/
L
60
40
20
0
m
g
/
d
L
150
120
90
60
30
0
C
m
m
o
l
/
L
16
12
8
4
0
E
m
g
/
d
L
0 0.5 (3d) 1 2 4 6 8 10 12 14 16
Week
0 0.5
(3d)
1 2 4 6 8 10
Control
SalpIL2
12 14 16
D
0.4
0.3
0.2
0.0
0.1
Week
0 0.5
(3d)
1 2 4 6 8 10 12 14 16
Week
0 0.5 (3d) 1 2 4 6 8 10 12 14 16
Week
0 0.5
(3d)
1 2 4 6 8 10 12 14 16
Figure 1 The effect of a single oral administration of SalpIL2 on mouse serum chemistry.   Asterisks indicate statistically significant changes in serum chemistry as determined 
by unpaired Student’s t-test. Results presented are mean values from groups of five SalpIL2-treated and five saline control animals.
Notes: error bars represent one standard deviation.   Alkaline phosphatase is denoted as Alk . *P  0.05, **P  0.01.Biologics: Targets & Therapy 2010:4 66
Sorenson et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
In one control animal at 10 weeks, there was marked histo-
lytic cell infiltration of the bone marrow. Minimal to moder-
ate acute inflammation in the submucosa was observed in 
the stomachs of the SalpIL2-treated animals. In contrast, 
control animals showed decreased inflammation in the 
stomach during this period, and inflammation was absent in 
all animals by week 12. Intra-abdominal lymph nodes had 
minimal to moderate increased reticuloendothelial cells in 
the majority of treated mice at weeks 6 and 8, and in 1 treated 
animal at all other time points. Four control animals also 
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had reticuloendothelial cell hyperplasia. In the brain, two 
SalpIL2-treated mice in the 4-week group had mild, multi-
focal, lymphocytic infiltrates in the meninges. One of these 
mice had minimal cerebral cortical lymphocytic perivascular 
cuffing. Microscopic lesions were not observed in the thymus, 
intestines, heart, or kidney in SalpIL2-treated animals.
Splenic lymphocyte response to SalpIL2
Animals orally administered SalpIL2 had an increased splenic 
NK 1.1+ cell population by day 7 which remained elevated 
on days 14 (P  0.01) and 21 and returned to basal level by 
day 28 (Figure 4A). A significant increase in CD81 T cells 
(P  0.001) on day 3 was observed followed by a return to 
baseline by day 7 (Figure 4B). SalpIL2 did not significantly 
alter the proportion of CD41 T cells over the 28-day period 
(Figure 4C).
hepatic metastasis model in Rag-1-/-
To elucidate the role of cytotoxic T cells in the SalpIL2 
  antitumor response, we used Rag-1-/- mice, which do not have 
mature B or T cells, in an experimental hepatic metastasis 
model. A single oral dose of Sal-NG or SalpIL2 significantly 
decreased tumor volume with respect to saline controls 
(P  0.001; Figure 5A). Furthermore, compared to saline 
controls and Sal-NG, SalpIL2 significantly increased hepatic 
NK cell populations detected by flow cytometry (P  0.001 
and P  0.05 respectively; Figure 5B).
Serum cytokine analysis in experimental 
osteosarcoma treatment model
The K7M2 murine osteosarcoma cell line was derived and 
characterized from spontaneous pulmonary metastases in 
Balb/c mice.13 Using an experimental lung metastasis model 
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that produces macroscopic lesions isolated to the lung, we 
analyzed sera from animals at 3-weeks post tumor injection. 
Serum cytokines in the treatment model were largely not 
significantly affected by oral administration of SalpIL2 or 
Sal-NG. Granulocyte colony-stimulating factor (G-CSF) was 
significantly increased from a control mean of 45.7 µg/mL 
to 107.7 µg/mL (P  0.05) in Sal-NG and 114.1 µg/mL 
(P  0.05) in SalpIL2 (Figure 6C). In addition, Sal-NG 
treated mice displayed 65% increase in IL-12p40 (P  0.05) 
whereas SalpIL2 treated mice did not display a significant 
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increase in IL-12p40 (Figure 6D). Systemic IL-2 was not 
significantly increased with SalpIL2 or Sal-NG oral gavage 
with respect to saline controls (Figure 6B).
Serum cytokine analysis in experimental 
prophylactic model
In the prophylactic model of pulmonary metastasis, several 
systemic cytokines were significantly lower in Sal-NG and 
SalpIL2 groups than in saline controls. Sal-NG significantly 
lowered IL-1β (P  0.01), KC (P  0.0257), and MCP-1 
(P  0.001) with respect to control animals (Figure 7). 
  SalpIL2 significantly decreased systemic IL-1β (P  0.001), 
IL-3 (P  0.0346), KC (P  0.01), MCP-1 (P  0.001), 
MIP-1β (P  0.05), and RANTES (P  0.05) compared to 
saline controls.
Discussion
Salmonella enterica serovar Typhimurium is a Gram-
  negative intracellular facultative anaerobe transmitted via 
the fecal-oral route. Upon oral administration, Salmonella 
migrate to the gastrointestinal tract and colonize lymphoid 
sections of the small intestine, called Peyer’s patches. In 
addition, intraepithelial dendritic cells provide a route for 
Salmonella to gain access to underlying tissues and other 
innate immune cells, thus circumventing the barrier provided 
by the intestinal epithelium.14 Salmonella-infected dendritic 
cells then migrate to the mesenteric lymph nodes for antigen 
processing.15 Apoptosis of infected macrophage and dendritic 
cells during their progression through the liver and spleen 
result in preferential colonization of these organs.16 Recent 
evidence suggests S. enterica’s survival in hepatic phago-
cytes includes the formation of a foci, release by necrosis 
or apoptosis, and invasion of surrounding cells that results 
in a new foci from a single bacteria.17,18 S. enterica’s colo-
nization of major organs and tissues may persist for up to 
a period of 4 to 6 months as a result of its ability to reside 
within an endosome as a facultative intracellular bacteria.19 
S. enterica Typhimurium is an attractive delivery vector for 
intra-tumoral expression of cytokines or antigenic molecules 
from viruses, bacteria, and some parasites in various animal 
models.20–26 Methods of Salmonella administration in cancer 
models varying from the oral route to intra-tumor or intra-
venous injections have been shown to be efficacious.27–29 
During our investigations we have examined the safety and 
efficacy of a single oral dose of the attenuated S. enterica 
Typhimurium χ4550 in reducing tumor burden in mice. 
The χ4550 strain is an adenylate cyclase, cyclic adenosine 
monophosphate receptor protein and aspartate semialdehyde 
dehydrogenase deletion mutant that does not express a func-
tional flagella.30 Oral administration of Salmonella may be 
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advantageous over intravenous delivery by allowing for use 
of standardized bacterial glycerol stocks and stimulation of 
both the systemic and mucosal immunity against intracellular 
pathogens. As argued by Belyakov and Ahlers, activating 
intraepithelial dendritic cells at mucosal surfaces produces 
a more robust response to intracellular pathogens including 
Salmonella.31 We have chosen to examine the safety and 
efficacy of a single oral dose in our models to reduce the 
potential inhibitory effects of the secretory IgA immune 
response against multiple Salmonella administrations.32 In 
prior investigations, a single oral dose of χ4550 engineered 
to express a human IL-2 activated NK cells against metastatic 
hepatic malignancies.9,26,33
Here we examined the antitumor mechanism of   
S. enterica expressing a C-terminal truncated human 
IL-2 gene. Supporting the pathological finding of a mild 
inflammatory response to a single oral administration of 
SalpIL2, splenic mononuclear lymphocytes were increased 
significantly within the first 7 days of oral administration, 
but returned to levels similar to control animals by week 4. 
Furthermore, oral SalpIL2 inoculation resulted in sporadic 
increases of inflammatory cells determined by CBC that 
gradually decreased as the study progressed. The MPV was 
decreased following SalpIL2 administration, while the total 
number of platelets present in the blood nearly doubled, 
likely due to hematopoietic stimulation in the spleen and 
bone marrow. White blood cells, eosinophils, monocytes 
and neutrophils were all increased in the first 2 weeks con-
sistent with concurrent infection. Recovery of SalpIL2 CFU 
was largely restricted to the liver and spleen and analysis of 
serum chemistries demonstrated no difference in liver or 
spleen function between control and SalpIL2-treated ani-
mals throughout the experiment. Some evidence of hepatic 
stress was expected as evidenced by the rise in Alk . Slight 
increases in Alk  at the week 6 sacrifice and normal bilirubin 
throughout demonstrate the ability of the infected animal 
to maintain normal liver enzymatic function despite mild 
hepatitis resulting from SalpIL2 infection. Acute increases 
in serum chloride were perceived to be a result of the gavage 
media. Renal function was determined to be unaffected as 
SalpIL2 administration resulted in only a slight decrease in 
serum BUN and creatinine concentrations at week 14 and a 
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slight increase of phosphorous at week 8. In some animals the 
volume of blood collected was not sufficient to examine all of 
the possible serum chemistry. Therefore some chemistry was 
unable to be examined at every sacrifice time point. Despite 
this limitation, we had a sufficient number of mice per group 
to determine the general systemic affects of a single oral dose 
of SalpIL2. Most importantly no SalpIL2-treated animal had 
detectable CFUs after 10 weeks of infection or displayed 
outward signs of morbidity, demonstrating the ability of the 
bacteria to be cleared without antibiotic treatment.
Based on these results, SalpIL2 did not produce a viru-
lent disease state in mice. We were unable to demonstrate 
morbidity associated with mild hepatitis, or any significant 
organ dysfunction. The treatment and control animals main-
tained food consumption within normal established limits. 
Although a few SalpIL2-treated mice developed meningitis 
and cerebritis, this observation was isolated to a single cage. 
It is unclear whether gavage technique or cage conditions 
may have resulted in SalpIL2 infection of the central ner-
vous system in those animals. Although the natural mode 
of Salmonella infection is fecal-oral, we were only able to 
culture SalpIL2 from the stool in one mouse over all time 
points. This may be a result of the innocula load or attenu-
ation of SalpIL2.
Oral administration of SalpIL2 did not create detectable 
systemic toxicity that may be cytotoxic to tumors in mice at 
any time point. Moderate increases in systemic NK and acute 
CD8+ T cell populations strongly suggest SalpIL2’s antitumor 
mechanism is cell-mediated tumor toxicity. As we reported 
previously, in a pulmonary metastasis model SalpIL2, 
but not Sal-NG, significantly increased NK but not CD8+ 
T cells in the lung relative to saline controls.7 Furthermore, 
depletion of liver NK cells and CD8+ T cells, but not CD4+ 
T cells and Kupffer, cells abrogated the antitumor effect 
of S. enterica species.26 Taken together, these data would 
suggest that although both SalpIL2 and Sal-NG can induce 
systemic NK cell proliferation, SalpIL2 is more efficient at 
attracting NK cells to distant tissues to direct an antitumor 
response. Because S. enterica preferentially tracks to and 
multiplies within tumors, biodistribution of SalpIL2 in tumor 
bearing animals may be augmented. Persistence of SalpIL2 
in tumors may prolong colonization of other tissues. How-
ever, mortality of animals with tumor significantly hinders 
any prolonged study on the differences in tumor-dependent 
SalpIL2 distribution.
To further elucidate the role of the immune system in 
SalpIL2’s antitumor response, we used Rag-1 deficient 
mice that have severely depressed B and T cells, including   
tumor-supportive regulatory T cell populations. NK cells 
lacking rearranged T cell receptors develop in the bone 
marrow but function and develop normally in Rag1 defi-
cient mice.11 Both Salmonella-treated groups significantly 
decreased tumor volume in a B and T-cell independent 
manner. SalpIL2, however, had significantly higher hepatic 
NK cell populations as compared to Sal-NG and saline 
controls. In animals with established pulmonary metasta-
ses, Salmonella-treatment increased expression of G-CSF, 
a chemokine that promotes monocyte activation and migra-
tion into tissues. These data suggest a strong cytotoxic 
immune response in the treatment animals. Most evident, in 
mice where tumors were introduced after Salmonella was 
administered, expression of several proinflammatory chemo-
kines was significantly reduced. However, these observations 
may be due to the decreased tumor burden in the animal and 
may not be reflective of the local cytokine environment of 
the tumor and warrant further study.
S. enterica Typhimurium tumor vaccines have become 
more prevalent in recent years. Many investigators have deter-
mined the efficacy of their vaccines through the injection of 
S. enterica Typhimurium directly into the tumor or through 
intravenous delivery.34,35 Administration of these S. enterica 
strains has been encouragingly efficacious in murine primary 
tumor models. S. enterica antigen vaccines, however, are 
dependant on homogenous tumor expression of the antigen 
to be effective against metastatic tumors.27 Investigators have 
shown intravenous administration of attenuated S. enterica to 
be safe in primates and humans in phase I clinical trials.36,37 
In our investigations, oral administration of SalpIL2 not only 
localized to the liver, spleen and pulmonary tissues, but also 
elicited a robust local and systemic NK cell response that was 
independent of tumor type or animal strain. In our pulmonary 
metastases model, osteosarcoma metastases formed clearly 
defined nodules and linear aggregates of invasive tumor 
cells centered around the pleura.7 Mononuclear infiltrate 
in SalpIL2-treated animals was positively correlated with 
a reduction in tumor burden and interpreted to represent 
tumor regression. Hence, the presence of mononuclear cell 
infiltrates appears to be an integral factor in the reduction of 
SalpIL2-treated tumors in vivo. Although oral administration 
induced a mild inflammatory response, these data strongly 
suggest SalpIL2 is avirulent, immunogenic, and induces a 
robust NK cell-mediated antitumor response.
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